Market Overview

BTIG Negative On Juno Therapeutics, Says Paper Reviewing CD8+ And CD4+ 'does not alter our Sell rating'

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for JUNO

DateFirmActionFromTo
Sep 2017BarclaysInitiates Coverage OnOverweight
Aug 2017Standpoint ResearchDowngradesBuyReduce
Aug 2017Raymond JamesUpgradesMarket PerformOutperform

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

Posted-In: Analyst Color Reiteration Analyst Ratings

 

Related Articles (JUNO)

Loading...